Baclofen for spasticity in multiple sclerosis Double‐blind crossover and three‐year study

Publisher Website
Google Scholar
Abstract
Baclofen is a safe and effective means for treating spasticity associated with multiple sclerosis in humans. No toxic effects were found on hepatologic, hematopoietic or renal function, acutely or for over 3 yr of follow-up. A statistically significant reduction was noted in frequency of spasms and clonus, and there was improved range of joint movement, which enabled patients to maintain functional status for prolonged periods. For the more disabled patients, treatment with baclofen gave symptomatic relief of painful spasms and made immobility more tolerable. Optimum effect was achieved when baclofen was administered in the early stages of disease, before major disabilities became permanent.

This publication has 0 references indexed in Scilit: